 Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic products ISELIN, N.J., Jan. 19, 2023 GLOBE NEWSWIRE Outlook Therapeutics, Inc. Nasdaq: OTLK, a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation ... The post Outlook Therapeutics Strengthens Medical Affairs and Commercial Expertise with Appoint... 